1 |
Tabang DN, Ford M, Li L. Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases. Front Chem 2021;9:707387. [PMID: 34368082 DOI: 10.3389/fchem.2021.707387] [Reference Citation Analysis]
|
2 |
Rivera D. Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer. Metabolites 2022;12:409. [DOI: 10.3390/metabo12050409] [Reference Citation Analysis]
|
3 |
Lageveen-Kammeijer GSM, Kuster B, Reusch D, Wuhrer M. High sensitivity glycomics in biomedicine. Mass Spectrom Rev 2021;:e21730. [PMID: 34494287 DOI: 10.1002/mas.21730] [Reference Citation Analysis]
|
4 |
Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, Petrelli F, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Cancers (Basel) 2021;13:4396. [PMID: 34503206 DOI: 10.3390/cancers13174396] [Reference Citation Analysis]
|
5 |
Vellan CJ, Jayapalan JJ, Yoong BK, Abdul-Aziz A, Mat-Junit S, Subramanian P. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review. Int J Mol Sci 2022;23:2093. [PMID: 35216204 DOI: 10.3390/ijms23042093] [Reference Citation Analysis]
|
6 |
Xu Y, Wang Y, Höti N, Clark DJ, Chen SY, Zhang H. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass Spectrom Rev 2021;:e21748. [PMID: 34766650 DOI: 10.1002/mas.21748] [Reference Citation Analysis]
|